Pheochromocytoma

Perspective Therapeutics’ VMT-α-NET Protocols Presented at the North American Neuroendocrine Tumor Society (NANETS) 2023 Symposium

Retrieved on: 
Tuesday, October 10, 2023

SEATTLE, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), today announced that two upcoming investigator-initiated trials (IIT) were presented at the North American Neuroendocrine Tumor Society (NANETS) 2023 Symposium in Montreal, Canada, which was held October 4-6, 2023.

Key Points: 
  • SEATTLE, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), today announced that two upcoming investigator-initiated trials (IIT) were presented at the North American Neuroendocrine Tumor Society (NANETS) 2023 Symposium in Montreal, Canada, which was held October 4-6, 2023.
  • Enrollment for this study is expected to commence in the first quarter of 2024.
  • “There are currently no approved targeted radiopharmaceuticals for NETs patients outside of the gastroenteropancreatic indication,” said Chief Executive Officer Thijs Spoor of Perspective Therapeutics.
  • “These clinical studies are evaluating [212Pb]VMT-alpha-NET in a wide range of neuroendocrine tumors, where the unmet need is greatest.”

Ariceum Therapeutics' targeted radiopharmaceutical 177Lu-satoreotide exhibits promising clinical response and good tolerability profile in patients with advanced neuroendocrine tumours

Retrieved on: 
Thursday, September 28, 2023

This international study was conducted in 7 countries - Australia, Austria, Canada, Denmark, France, Switzerland, and the UK - and enrolled 40 patients with advanced, SSTR2-positive NETs.

Key Points: 
  • This international study was conducted in 7 countries - Australia, Austria, Canada, Denmark, France, Switzerland, and the UK - and enrolled 40 patients with advanced, SSTR2-positive NETs.
  • The primary tumours of the patients included progressive, grade 1 and 2 (≈60%) gastroenteropancreatic (GEP), and (a)typical lung NETs, paraganglioma, and pheochromocytoma.
  • Manfred Rüdiger, PhD, Chief Executive Officer of Ariceum Therapeutics, said: "These exciting new data demonstrate the great potential of our targeted radiopharmaceutical, satoreotide, for treating patients with advanced neuroendocrine tumours.
  • A phase I/II study of the safety and efficacy of [177Lu]Lu-satoreotide tetraxetan in advanced somatostatin receptor-positive neuroendocrine tumours.

Ariceum Therapeutics' targeted radiopharmaceutical 177Lu-satoreotide exhibits promising clinical response and good tolerability profile in patients with advanced neuroendocrine tumours

Retrieved on: 
Thursday, September 28, 2023

This international study was conducted in 7 countries - Australia, Austria, Canada, Denmark, France, Switzerland, and the UK - and enrolled 40 patients with advanced, SSTR2-positive NETs.

Key Points: 
  • This international study was conducted in 7 countries - Australia, Austria, Canada, Denmark, France, Switzerland, and the UK - and enrolled 40 patients with advanced, SSTR2-positive NETs.
  • The primary tumours of the patients included progressive, grade 1 and 2 (≈60%) gastroenteropancreatic (GEP), and (a)typical lung NETs, paraganglioma, and pheochromocytoma.
  • Manfred Rüdiger, PhD, Chief Executive Officer of Ariceum Therapeutics, said: "These exciting new data demonstrate the great potential of our targeted radiopharmaceutical, satoreotide, for treating patients with advanced neuroendocrine tumours.
  • A phase I/II study of the safety and efficacy of [177Lu]Lu-satoreotide tetraxetan in advanced somatostatin receptor-positive neuroendocrine tumours.

Perspective Announces Presentation of Positive Early Clinical Data for VMT-α-NET at the 36th Annual Congress of the European Association of Nuclear Medicine

Retrieved on: 
Tuesday, September 12, 2023

Responses observed in both peptide receptor radionuclide therapy-naïve and peptide receptor radionuclide therapy-refractory disease.

Key Points: 
  • Responses observed in both peptide receptor radionuclide therapy-naïve and peptide receptor radionuclide therapy-refractory disease.
  • The results were presented at the 36th Annual Congress of the European Association of Nuclear Medicine (EANM), held in Vienna, Austria, from September 9-13, 2023.
  • Improvements in patients’ symptoms and quality of life trended strongly positive with consecutive [212Pb]VMT-α-NET doses.
  • We will continue to monitor patients’ progress, and we look forward to providing a more extensive data readout in the upcoming quarters.”

Carling Adrenal Center Spotlights Pheochromocytoma: The Common Adrenal Tumor You've Never Heard Of--But Could Be Making You Sick

Retrieved on: 
Wednesday, August 23, 2023

Pheochromocytoma is a tumor that originates in the adrenal glands , situated above the kidneys.

Key Points: 
  • Pheochromocytoma is a tumor that originates in the adrenal glands , situated above the kidneys.
  • The founder of the Carling Adrenal Center, Dr. Tobias Carling , has spent decades dedicated to refining surgical techniques, research, and raising awareness about pheochromocytoma.
  • Dr. Carling and the Carling Adrenal Center team operate exclusively at the Hospital for Endocrine Surgery in Tampa, Florida.
  • The Hospital for Endocrine Surgery is home to the Carling Adrenal Center, Clayman Thyroid Center , and Norman Parathyroid Center .

Lilly to Divest BAQSIMI to Amphastar

Retrieved on: 
Monday, April 24, 2023

INDIANAPOLIS and RANCHO CUCAMONGA, Calif., April 24, 2023 /PRNewswire/ -- In an effort to continue expanding the availability of BAQSIMI® to patients, Eli Lilly and Company (NYSE: LLY) and Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) have entered into a definitive agreement for Lilly to divest BAQSIMI worldwide to Amphastar, a global pharmaceutical company focused on developing, manufacturing, and marketing injectable, intranasal, and inhalation products including experience with a glucagon product. BAQSIMI is the first and only nasally administered glucagon for the treatment of severe hypoglycemia in people with diabetes.

Key Points: 
  • INDIANAPOLIS and RANCHO CUCAMONGA, Calif., April 24, 2023 /PRNewswire/ -- In an effort to continue expanding the availability of BAQSIMI® to patients, Eli Lilly and Company (NYSE: LLY) and Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) have entered into a definitive agreement for Lilly to divest BAQSIMI worldwide to Amphastar, a global pharmaceutical company focused on developing, manufacturing, and marketing injectable, intranasal, and inhalation products including experience with a glucagon product.
  • Amphastar expects to provide dedicated commercial investment for BAQSIMI with the goal of enabling more people on insulin to be prepared with a glucagon rescue treatment for severe hypoglycemia.
  • Lilly launched BAQSIMI in 2019 as an option to quickly render aid in rescue situations for people with diabetes who take insulin and it is currently available in 27 international markets.
  • Each of Lilly and Amphastar will determine their applicable accounting treatment for this transaction according to Generally Accepted Accounting Principles (GAAP) upon closing.

Evoke Pharma Strengthens its Intellectual Property Portfolio with a Notice of Allowance from the USPTO for a Patent Application Related to GIMOTI®

Retrieved on: 
Wednesday, November 30, 2022

This patent application is a continuation of several other U.S. patent applications filed by the company over the last decade.

Key Points: 
  • This patent application is a continuation of several other U.S. patent applications filed by the company over the last decade.
  • We are thrilled and highly encouraged by the strides we have made with the USPTO and its continued acknowledgement of the novel and inventive nature of GIMOTI, said Matt DOnofrio, Chief Business Officer of Evoke Pharma.
  • Most common adverse reactions (5%) for GIMOTI are: dysgeusia, headache, and fatigue.These are not all of the possible side effects of GIMOTI.
  • Call your doctor for medical advice about whether you should take GIMOTI and the possible risk factors and side effects.

Evoke Pharma to Participate in the 2022 American College of Gastroenterology Annual Scientific Meeting

Retrieved on: 
Thursday, October 20, 2022

SOLANA BEACH, Calif., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases, today announced that the Company will participate in the 2022 American College of Gastroenterology Annual Scientific Meeting taking place from October 21 – 26, 2022 in Charlotte, North Carolina. Also, as a nominee for the Healio Industry Breakthrough Product Award, Evoke will attend the Healio Disruptive Innovators Awards Program on Sunday, October 23rd, in Charlotte during the ACG meeting.

Key Points: 
  • FollowEvoke Pharmaon Facebook: https://www.facebook.com/Evoke-Pharma-Inc-131313647029724
    FollowEvoke Pharmaon LinkedIn: https://www.linkedin.com/company/evoke-pharma/
    GIMOTI is indicated for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis.
  • Evoke cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements.
  • The inclusion of forward-looking statements should not be regarded as a representation by Evoke that any of its plans will be achieved.
  • This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

GIMOTI Receives Nomination for 2022 Healio Industry Breakthrough Award

Retrieved on: 
Wednesday, September 14, 2022

SOLANA BEACH, Calif., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, today announced that its flagship product, GIMOTI has been nominated for Healio’s Annual Disruptive Innovators Awards under the Healio Industry Breakthrough Award category. GIMOTI was selected amongst other novel gastroenterology products from major pharmaceutical companies.

Key Points: 
  • The Disruptive Innovators Awards hosted by Healio is an annual event to celebrate the trailblazers, movers, and industry name-makers that are creating a revolution in gastroenterology.
  • "We are extremely honored to receive the nomination for GIMOTI as a Healio Disruptive Innovator.
  • We look forward to the Healio organization's unveiling of the award winners in each category and encourage all Evoke supporters to access the Healio survey and vote for GIMOTI."
  • Most common adverse reactions (5%) for GIMOTI are: dysgeusia, headache, and fatigue.These are not all of the possible side effects of GIMOTI.